Dr. Jill Kickul served as a professor at the Lloyd Greif Center for Entrepreneurial Studies and Narayan Research Director of the Brittingham Social Enterprise Lab, both at the Marshall School of Business of the University of Southern California in the United States. She was also the academic director of the Master of Science in Social Entrepreneurship at the same institution. Furthermore, she is the founding director of the Annual Social Entrepreneurship Conference, the largest academic conference in the field.

Jill Kickul was previously director of the Social Entrepreneurship program at NYU’s Stern School of Business and academic advisor for the MBA’s Social Innovation and Impact Specialization. She also held several distinguished positions, such as president of the United States Association for Small Business and Entrepreneurship (USASBE) in 2020, and was part of the Research Committee Chair (2018-2020) and the Teaching Committee Chair (2009-2012) for the Academy of Management, both in the Entrepreneurship Division.

Her career has been marked by a focus on entrepreneurial studies and social enterprise, where she combines her expertise in research with practical applications in these fields. Her work primarily revolves around understanding and fostering entrepreneurship, particularly emphasizing social entrepreneurship and its impact on society.

Dr. Kickul received the 2022 Dedication to Entrepreneurship Award from the Academy of Management, recognizing her long-term contributions to entrepreneurship research, teaching, practice, and the field’s growth.

Jill Kickul joined Tecnológico de Monterrey as a Distinguished Professor in Social Entrepreneurship for the Business School and EGADE Business School.

• Ph.D., Industrial/Organizational Psychology, Northern Illinois University.
• M.A., Industrial/Organizational Psychology, Northern Illinois University.
• MBA, DePaul University.

Dr. Carlos Aguilar is an expert on the pathophysiology, treatment, and management of dyslipidemias and type 2 diabetes in Mexico. He is a surgeon specializing in Internal Medicine and Endocrinology and holds a doctorate in Medical Research. His main contributions include: participating in the identification of new genes involved in the pathophysiology of Familial Combined Hyperlipidemia; being part of the team that conducted the first genome-wide study to identify the genetic variants that modulate plasma lipid levels in Mexicans; and helping identify the R230C variant of the ABC-A1 transporter (a variant specific to Amerindian populations) as a determinant of HDL cholesterol concentrations in Mexicans, among others.

Since 1996, he has been deputy chief of the Department of Endocrinology and Metabolism of the National Institute of Medical Sciences and Nutrition (Mexico) and has been coordinator of the
Ethics Committee of the National Institute of Medical Sciences and Nutrition since 2012. He is also a member of the National Academy of Medicine and has held positions such as director of examinations of the Mexican Board of Endocrinology and president of the Mexican Society of Nutrition and Endocrinology. 

Carlos Aguilar is a Level III researcher with the National System of Researchers in Mexico and a Level F researcher with the National Institutes of Health in the U.S. His scientific output is prolific, with more than 540 articles published in peer-reviewed and/or indexed journals and 66,711 citations. His research focuses on the peculiarities of metabolic diseases in Mexican mestizos, such as the pathophysiology of primary dyslipidemias, the epidemiology of type 2 diabetes, the development of predictive models for type 2 diabetes and its comorbidities, and the characterization of the mechanisms by which certain genetic variants are associated with type 2 diabetes. He received Mexico’s National Science Award in 2018.

Carlos Aguilar joined Tecnológico de Monterrey as Distinguished Visiting Professor in Epidemiology at the School of Medicine and Health Sciences.

• Doctorate in Medical Research, Escuela Superior de Medicina, Instituto Politécnico Nacional
• Research stay at the Division of Atherosclerosis and Lipid Research, Washington University
• Specialty in Endocrinology, Instituto Nacional de la Nutrición
• Specialty in Internal Medicine, Instituto Nacional de la Nutrición
• Medical Surgeon, Universidad Nacional Autónoma de México (UNAM)

• Rojas-Martínez R, Escamilla-Nuñez C, Aguilar-Salinas CA, Castro-Porras L, Romero-Martínez M, Lazcano-Ponce E. Trends in the mortality of diabetes in Mexico from 1998 to 2022: a joinpoint regression and age-period-cohort effect analysis. Public Health. 2023 Dec 5;226:128-137. doi: 10.1016/j.puhe.2023.10.038
• Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, Rivera JA, Romero-Martinez M, Barquera S, Barrientos-Gutiérrez T. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023 Jun 13;65:s163-s168. doi: 10.21149/14832
• Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A, Barrientos-Gutiérrez T, Romero-Martínez M, Aguilar-Salinas C. Tamizaje, prevalencia, diagnóstico previo, tratamiento y control de hipertensión, hipercolesterolemia y diabetes en adultos mexicanos. Ensanut 2022. Salud Publica Mex. 2023 Nov 13;65(6, nov-dic):685-696. doi: 10.21149/15060
• Rivera-Alcántara JA, Esparza-Hurtado N, Galán-Ramírez GA, Cruz-Bautista I, Mehta R, Aguilar-Salinas CA, Martagon AJ. A systematic review of biobanks in Latin America: Strengths and limitations for biomedical research. Int J Biol Markers. 2024 Apr 13:3936155241239672. doi: 10.1177/03936155241239672. PMID: 38613331.
• Vargas-Vázquez A, Fermín-Martínez CA, Antonio-Villa NE, Fernández-Chirino L, Ramírez-García D, Dávila-López G, Díaz-Sánchez JP, Aguilar-Salinas CA, Seiglie JA, Bello-Chavolla OY. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes. Atherosclerosis. 2024 Mar 13:117508. doi: 10.1016/j.atherosclerosis.2024.117508. PMID: 38570208.
• Sohail M, Palma-Martínez MJ, Chong AY, Quinto-Cortés CD, Barberena-Jonas C, Medina-Muñoz SG, Ragsdale A, Delgado-Sánchez G, Cruz-Hervert LP, Ferreyra-Reyes L, Ferreira-Guerrero E, Mongua-Rodríguez N, Canizales-Quintero S, Jimenez-Kaufmann A, Moreno-Macías H, Aguilar-Salinas CA, Auckland K, Cortés A, Acuña-Alonzo V, Gignoux CR, Wojcik GL, Ioannidis AG, Fernández-Valverde SL, Hill AVS, Tusié-Luna MT, Mentzer AJ, Novembre J, García-García L, Moreno-Estrada. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023 Oct 11. doi: 10.1038/s41586-023-06560-0 

More information

Dr. Carlos Aguilar is an expert on the pathophysiology, treatment, and management of dyslipidemias and type 2 diabetes in Mexico. He is a surgeon specializing in Internal Medicine and Endocrinology and holds a doctorate in Medical Research. His main contributions include: participating in the identification of new genes involved in the pathophysiology of Familial Combined Hyperlipidemia; being part of the team that conducted the first genome-wide study to identify the genetic variants that modulate plasma lipid levels in Mexicans; and helping identify the R230C variant of the ABC-A1 transporter (a variant specific to Amerindian populations) as a determinant of HDL cholesterol concentrations in Mexicans, among others.

Since 1996, he has been deputy chief of the Department of Endocrinology and Metabolism of the National Institute of Medical Sciences and Nutrition (Mexico) and has been coordinator of the
Ethics Committee of the National Institute of Medical Sciences and Nutrition since 2012. He is also a member of the National Academy of Medicine and has held positions such as director of examinations of the Mexican Board of Endocrinology and president of the Mexican Society of Nutrition and Endocrinology. 

Carlos Aguilar is a Level III researcher with the National System of Researchers in Mexico and a Level F researcher with the National Institutes of Health in the U.S. His scientific output is prolific, with more than 540 articles published in peer-reviewed and/or indexed journals and 66,711 citations. His research focuses on the peculiarities of metabolic diseases in Mexican mestizos, such as the pathophysiology of primary dyslipidemias, the epidemiology of type 2 diabetes, the development of predictive models for type 2 diabetes and its comorbidities, and the characterization of the mechanisms by which certain genetic variants are associated with type 2 diabetes. He received Mexico’s National Science Award in 2018.

Carlos Aguilar joined Tecnológico de Monterrey as Distinguished Visiting Professor in Epidemiology at the School of Medicine and Health Sciences.

• Doctorate in Medical Research, Escuela Superior de Medicina, Instituto Politécnico Nacional
• Research stay at the Division of Atherosclerosis and Lipid Research, Washington University
• Specialty in Endocrinology, Instituto Nacional de la Nutrición
• Specialty in Internal Medicine, Instituto Nacional de la Nutrición
• Medical Surgeon, Universidad Nacional Autónoma de México (UNAM)

• Rojas-Martínez R, Escamilla-Nuñez C, Aguilar-Salinas CA, Castro-Porras L, Romero-Martínez M, Lazcano-Ponce E. Trends in the mortality of diabetes in Mexico from 1998 to 2022: a joinpoint regression and age-period-cohort effect analysis. Public Health. 2023 Dec 5;226:128-137. doi: 10.1016/j.puhe.2023.10.038
• Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, Rivera JA, Romero-Martinez M, Barquera S, Barrientos-Gutiérrez T. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023 Jun 13;65:s163-s168. doi: 10.21149/14832
• Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A, Barrientos-Gutiérrez T, Romero-Martínez M, Aguilar-Salinas C. Tamizaje, prevalencia, diagnóstico previo, tratamiento y control de hipertensión, hipercolesterolemia y diabetes en adultos mexicanos. Ensanut 2022. Salud Publica Mex. 2023 Nov 13;65(6, nov-dic):685-696. doi: 10.21149/15060
• Rivera-Alcántara JA, Esparza-Hurtado N, Galán-Ramírez GA, Cruz-Bautista I, Mehta R, Aguilar-Salinas CA, Martagon AJ. A systematic review of biobanks in Latin America: Strengths and limitations for biomedical research. Int J Biol Markers. 2024 Apr 13:3936155241239672. doi: 10.1177/03936155241239672. PMID: 38613331.
• Vargas-Vázquez A, Fermín-Martínez CA, Antonio-Villa NE, Fernández-Chirino L, Ramírez-García D, Dávila-López G, Díaz-Sánchez JP, Aguilar-Salinas CA, Seiglie JA, Bello-Chavolla OY. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes. Atherosclerosis. 2024 Mar 13:117508. doi: 10.1016/j.atherosclerosis.2024.117508. PMID: 38570208.
• Sohail M, Palma-Martínez MJ, Chong AY, Quinto-Cortés CD, Barberena-Jonas C, Medina-Muñoz SG, Ragsdale A, Delgado-Sánchez G, Cruz-Hervert LP, Ferreyra-Reyes L, Ferreira-Guerrero E, Mongua-Rodríguez N, Canizales-Quintero S, Jimenez-Kaufmann A, Moreno-Macías H, Aguilar-Salinas CA, Auckland K, Cortés A, Acuña-Alonzo V, Gignoux CR, Wojcik GL, Ioannidis AG, Fernández-Valverde SL, Hill AVS, Tusié-Luna MT, Mentzer AJ, Novembre J, García-García L, Moreno-Estrada. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023 Oct 11. doi: 10.1038/s41586-023-06560-0 

More information